Check out your Company Bowl for anonymous work chats.
BostonGene Announces New Master Agreement with Leading Cancer Center in New York City
BostonGene to Present at the 2022 American Society of Clinical Oncology Annual Meeting
BostonGene Announces Integration With NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)
BostonGene Announces Acceptance of Six Abstracts to be Presented at the American Association for Cancer Research Annual Meeting 2022
BostonGene Announces $150 Million Series B Funding at a Multi-Billion Dollar Valuation, Propelling the Company to Unicorn Status
BostonGene and Thomas Jefferson University Announce Publication in Clinical Cancer Research Predicting Immunotherapy Response for Patients with Head and Neck Cancer
BostonGene Earns Recognition from Cancer Cell for its State-of-the-Art Technology in Cancer Research and Oncology
BostonGene Expands Testing Capabilities to Predict Patient Response to Immunotherapy
BostonGene and WellDyne Announce Strategic Partnership to Predict Immunotherapy Response and Reduce Overall Cost of Care in Cancer
BostonGene and NEC Announce Global Partnership
